Scientific publications

Scientific articles authored by Novo Nordisk

The information you can search here is retrieved via the database Current Contents®, covering 95% of publications within the life science area. Only articles authored by at least one researcher from Novo Nordisk are included in the search results. The database provides easy access to tables of contents, abstracts, bibliographic information, and abstracts from the most recently published issues of leading scholarly journals.


Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency

Author(s): Inbal A ; Oldenburg J ; Carcao M ; Rosholm A ; Tehranchi R ; Nugent D

Corporate source(s)

Nugent D, UC Irvine Med Sch, Childrens Hosp Orange County, Dept Hematol, 455 S Maine St, Orange, CA 92868 USA, dnugent@choc.org

Source

Blood 2012, Vol. 119, pg. 5111-5117

Abstract

Congenital factor XIII (FXIII) deficiency is a rare, autosomal-recessive disorder, with most patients having an A- subunit (FXIII-A) deficiency. Patients experience life- threatening bleeds, impaired wound healing, and spontaneous abortions. In many countries, only plasma or cryoprecipitate treatments are available, but these carry a risk for allergic reactions and infection with blood-borne pathogens. The present study was a multinational, open-label, single-arm, phase 3 prophylaxis trial evaluating the efficacy and safety of a novel recombinant FXIII (rFXIII) in congenital FXIII-A subunit deficiency. Forty-one patients >= 6 years of age (mean, 26.4; range, 7-60) with congenital FXIII-A subunit deficiency were enrolled. Throughout the rFXIII prophylaxis, only 5 bleeding episodes (all trauma induced) in 4 patients were treated with FXIII-containing products. The crude mean bleeding rate was significantly lower than the historic bleeding rate (0.138 vs 2.91 bleeds/patient/year, respectively) for on-demand treatment. Transient, non- neutralizing, low-titer anti-rFXIII Abs developed in 4 patients, none of whom experienced allergic reactions, any bleeds requiring treatment, or changes in FXIII pharmacokinetics during the trial or follow-up. These non- neutralizing Abs declined below detection limits in all 4 patients despite further exposure to rFXIII or other FXIII- containing products. We conclude that rFXIII is safe and effective in preventing bleeding episodes in patients with congenital FXIII-A subunit deficiency. This study is registered at http://www..clinicaltrials.gov as number NCT00713648. (Blood. 2012; 119(22): 5111-5117)

BackBack